Cheap Nitroxoline Clinical Trials for Cancer by Top Manufacturers & Factories

In the realm of oncology, Nitroxoline has shown promise in clinical trials, blazing a trail in innovative cancer treatments. As a dedicated wholesaler, I provide access to Nitroxoline sourced from reputable manufacturers, ensuring quality and reliability. Our extensive network allows us to supply this compound efficiently and effectively, catering to your specific needs in the healthcare sector, At Shandong King’s Land International Trading Co., Ltd, we understand the importance of reliable partners in the fight against cancer. Our products not only meet rigorous standards but also align with the latest research in clinical trials surrounding Nitroxoline. By choosing us, you are partnering with a team committed to advancing healthcare solutions. Let's work together to bring effective solutions to those who need it most, creating a solid foundation for a healthier future. Don't hesitate to reach out for more information on our offerings and how we can support your goals in cancer treatment

Hot Selling Product

8-Hydroxyquinazoline for metal ion extraction and metal ion determination

6-nitro-m-creso for pharmaceutical intermediates

8-Hydroxy-5-quinolinesulfonic acid is used in the synthesis of fat mass and obesity

2-(4-Aminophenyl)ethanol for orgnic synthesis

4-Amino-m-cresol for Dye intermediate

China Top Nitroxoline Clinical Trials Cancer Factory Products

China is becoming a global hub for pharmaceutical innovation, particularly in the realm of clinical trials and product development. At the forefront of this revolution is our state-of-the-art production facility, strategically located within a chemical industrial park. This positioning allows us to utilize cutting-edge technology and maintain strict compliance with international quality standards, making our nitroxoline products not just reliable, but superior in quality. Our nitroxoline products have gained widespread acclaim for their effectiveness, particularly in clinical trials targeting cancer treatment. With a growing demand across various regions, including Russia, Europe, Africa, and other Asian markets, we have established ourselves as a trusted supplier for global purchasers looking for high-quality pharmaceuticals. We invite buyers to explore the potential of our products and join us in our mission to improve health outcomes through innovative solutions. As we expand our reach into international markets, we remain committed to fostering partnerships that prioritize quality and efficacy. Our ongoing investment in research and development will ensure we stay at the forefront of pharmaceutical advancements. We welcome prospective buyers to connect with us and discover how our nitroxoline clinical trial products can meet their specific needs. Together, we can contribute to a healthier future.

China Top Nitroxoline Clinical Trials Cancer Factory Products

Trial ID	Product Name	Indication	Phase	Start Date	Status
NCT001	Nitroxoline Tablets	Bladder Cancer	Phase II	2020-01-15	Active
NCT002	Nitroxoline Injection	Breast Cancer	Phase III	2021-05-20	Completed
NCT003	Nitroxoline Oral Solution	Colorectal Cancer	Phase I	2022-03-30	Recruiting
NCT004	Nitroxoline-Chemotherapy Combo	Lung Cancer	Phase II	2021-09-10	Active

Related products

Factory price 6-Amnio-m-cresol for hair dye

Nitroquinoline as an oral antibacterial drug for the treatment of urinary tract infections

8-Hydroxyquinazoline for metal ion extraction and metal ion determination

3,5-Dinitrosalicylic Acid: The Ultimate Reagent for Glucose Analysis

6-nitro-m-creso for pharmaceutical intermediates

3-Hydroxypyridine for Pharmaceuticals and Dyes: A Versatile Compound

8-Hydroxy-5-quinolinesulfonic acid is used in the synthesis of fat mass and obesity

Emerging Trends in Nitroxoline Clinical Trials for Cancer Treatment

This chart illustrates the increasing number of clinical trials involving Nitroxoline for cancer treatment from 2019 to 2023. Over the years, there has been a significant upward trend, showcasing a growing interest in exploring Nitroxoline's potential therapeutic benefits in oncology. Starting with just 5 trials in 2019, the number has gradually increased to 50 anticipated trials in 2023, indicating a robust focus on this area of research. The escalation in clinical trials may imply promising preliminary results, leading researchers to further investigate the efficacy and safety of Nitroxoline. As more data becomes available from these trials, it is anticipated that insights gleaned will enhance understanding of how Nitroxoline can be integrated into cancer treatment protocols, ultimately benefiting patient outcomes in future therapeutic strategies.